Vicore Pharma Holding Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Ahmed Mousa
Chief executive officer
SEK 8.3m
Total compensation
| CEO salary percentage | 54.19% |
| CEO tenure | 2.3yrs |
| CEO ownership | n/a |
| Management average tenure | 1.3yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate
Apr 24
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate
Sep 11Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans
Feb 10We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
Sep 21We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
May 25Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)
Jan 10Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?
Nov 13Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation
Jul 26Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?
Mar 03What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition
Jan 11
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -SEK 312m |
| Dec 31 2024 | SEK 8m | SEK 5m | -SEK 169m |
| Sep 30 2024 | n/a | n/a | -SEK 196m |
| Jun 30 2024 | n/a | n/a | -SEK 200m |
| Mar 31 2024 | n/a | n/a | -SEK 213m |
| Dec 31 2023 | SEK 6m | SEK 1m | -SEK 311m |
Compensation vs Market: Ahmed's total compensation ($USD875.12K) is above average for companies of similar size in the Swedish market ($USD522.17K).
Compensation vs Earnings: Ahmed's compensation has increased whilst the company is unprofitable.
CEO
Ahmed Mousa (40 yo)
Mr. Ahmed S. Mousa, J. D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.3yrs | SEK 8.35m | no data | |
| Chief Financial Officer | 7.9yrs | no data | 0.0021% SEK 39.9k | |
| Chief Operating Officer | 1.3yrs | no data | 0.0017% SEK 32.2k | |
| Chief Scientific Officer | 7.3yrs | no data | 0.10% SEK 1.9m | |
| Chief Medical Officer | 1.4yrs | no data | no data | |
| VP & Head of CMC | 1.3yrs | no data | no data | |
| Head of Quality Assurance | less than a year | no data | no data | |
| Head of Clinical Operations | less than a year | no data | no data | |
| Head of Global Medical Affairs | less than a year | no data | no data | |
| Vice President of Business Development | 1.3yrs | no data | no data |
Experienced Management: VICO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 7.3yrs | SEK 575.00k | 0.0027% SEK 51.2k | |
| Independent Director | 2yrs | SEK 409.00k | no data | |
| Independent Director | 1yr | SEK 322.00k | no data | |
| Independent Director | 1yr | SEK 397.00k | no data | |
| Independent Chairman | 6.8yrs | SEK 1.04m | 0.0017% SEK 32.1k | |
| Independent Director | 2yrs | SEK 437.00k | no data | |
| Independent Director | 5yrs | SEK 520.00k | 0.0021% SEK 39.9k |
Experienced Board: VICO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 19:53 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vicore Pharma Holding AB (publ) is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hanseung Yoo | Bryan Garnier & Co |
| Oscar Haffen Lamm | Bryan Garnier & Co |
| Gonzalo Artiach Castanon | Danske Bank |